Brought to you by 
Vectura to buy SkyePharma for $621mm
08 Sep 2020
Executive Summary
Vectura Group PLC agreed to buy SkyePharma PLC for consideration of $621mm (£441mm). SkyePharma shareholders will receive 2.7977 new shares for each share held (£441.3mm valuation; 410.15p per share representing 7% premium over prior 10-day trading average). Alternatively shareholders can choose to receive partial consideration in cash. Annual pre-tax synergies are expected to be around £10mm, and will be fully realized by 2018.
Deal Industry
- Biotechnology
- Medical Devices
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Pulmonary
- Topical Delivery
-
Drug Delivery
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Intra-Biotech Deal
- Payment Includes Cash
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Vectura to buy SkyePharma for $621mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice